Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Historic Current Leases for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $2.3 million.

  • Keros Therapeutics' Current Leases rose 2482.5% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 2482.5%. This contributed to the annual value of $2.0 million for FY2024, which is 9681.59% up from last year.
  • Keros Therapeutics' Current Leases amounted to $2.3 million in Q3 2025, which was up 2482.5% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Current Leases ranged from a high of $2.3 million in Q3 2025 and a low of $436000.0 during Q1 2021
  • Its 5-year average for Current Leases is $1.1 million, with a median of $884000.0 in 2022.
  • As far as peak fluctuations go, Keros Therapeutics' Current Leases plummeted by 4721.58% in 2022, and later skyrocketed by 20392.8% in 2024.
  • Keros Therapeutics' Current Leases (Quarter) stood at $862000.0 in 2021, then tumbled by 47.22% to $455000.0 in 2022, then soared by 120.88% to $1.0 million in 2023, then soared by 96.82% to $2.0 million in 2024, then rose by 17.19% to $2.3 million in 2025.
  • Its Current Leases stands at $2.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.1 million for Q1 2025.